The new blood test predicts which patient with COVID-19 will have a serious infection

For the first time, scientists have developed a scale that can predict exactly which patient will develop severe form Covid-19.

The study was led by researchers at the RCSI University of Medicine and Health Sciences, published in The Lancet’s journal EBioMedicine translation research.

The measurement, known as the Dublin-Boston score, is designed to allow clinicians to make more informed decisions when determining which patients may benefit from therapies, such as steroids and hospital admissions. special squirrel.

Until this study was available, there was no specific Covid-19 prognostic score to guide clinical decision-making. The Dublin-Boston score can now accurately predict the prevalence of the infection on the Saturday after measuring the patient’s blood for the first four days.

Blood tests work by measuring the level of two molecules that send messages to the body’s immune system and control inflammation. One of these molecules, interleukin (IL) -6, is an anti-inflammatory and another, called IL-10. The levels of both varied in patients with severe Covid-19.

Based on the change in the ratios of these two fractions over time, the researchers developed a point system where each 1 point increase is associated with a 5.6x increase for the outcome. be more serious.

“The Dublin-Boston score is easily calculated and applicable to all Covid-19 hospitalized patients,” RCSI Medical Professor Gerry McElvaney, study lead author and consultant at Beaumont Hospital. said.

A fuller prognosis can help determine when to escalate or reduce care escalation, a key component of efficient resource allocation in today’s pandemic. Scores may also play a role in assessing whether new therapies designed to reduce inflammation in Covid-19 are indeed beneficial.

The Dublin-Boston score uses the ratio of IL-6 to IL-10 because it is significantly superior to measuring change in IL-6 alone.

Despite the high concentration in the blood, the use of only IL-6 measurements as a Covid-19 prognostic tool was hampered by a number of factors. The level of IL-6 in the same patient varies over any given day, and the level of the IL-6 response to the infection differs between patients.


Leave a Reply

Your email address will not be published. Required fields are marked *